Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00091819 · ClinicalTrials.gov registry record · Phase 3
Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus
A Phase 3 study, sponsored by Cumberland Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 862
- Enrollment target
NCT00091819 is a Phase 3 study that has completed, run by Cumberland Pharmaceuticals. The registered enrollment target is 862 participants.
The verdict
NCT00091819, a Phase 3 study, has completed, sponsored by Cumberland Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 862 participants
- Enrollment target
Study Summary
Study 0017 compares the safety and effectiveness of an investigational drug, telavancin, and an approved drug, vancomycin, for the treatment of complicated skin and skin structure infections.
Interventions
- DRUG Vancomycin
- DRUG Telavancin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 862 participants |
| Start Date | 2005-01 |
| Est. Completion | 2006-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00091819
The ClinicalTrials.gov registry entry for NCT00091819 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 862 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cumberland Pharmaceuticals, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vancomycin is the first listed.
NCT00091819 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00091819 about?
NCT00091819 is a clinical study titled "Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus". Study 0017 compares the safety and effectiveness of an investigational drug, telavancin, and an approved drug, vancomycin, for the treatment of complicated skin and skin structure infections.
What is the current status of trial NCT00091819?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 862 participants. The study started on 2005-01. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00091819?
The interventions under investigation include: Vancomycin (DRUG), Telavancin (DRUG).
Who is sponsoring clinical trial NCT00091819?
This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.